Obsbot's Tiny 3 is, at its core, a superb 4K webcam for a premium price. The accompanying software is problematic: there are ...

Novo Nordisk is facing a massive wave of generic competitors to its injectable formulations of GLP-1 agonist semaglutide, used to treat diabetes and obesity, as a key patent in India is due to expire ...

Build first, understand later.

In India, China and other nations, Novo Nordisk is on the verge of losing patent protection for its blockbuster weight loss drug, opening the door for cheaper competing versions.

Generics Awareness Month took center stage at the Mercury Drug Q-Plaza Branch in Cainta recently, where RHEA Generics, in support of the Department of Health (DOH) and in partnership with Mercury Drug ...

The weight-loss world is on the brink of a major shake-up. Pharmaceutical companies in India will get the green light this weekend to start selling generic versions of Ozempic and Wegovy, with several ...

A patient walks into a clinic and asks not about diabetes control, but about weight loss drug. He has seen the results online, heard the name of the drug, and now, with prices falling, wants it.

MUMBAI: Natco Pharma has heralded what could become an intense pricing war in India’s pharmaceutical sector by offering its generic version of semaglutide at 90% cheaper than the original weight-loss ...

All the Indian generics are substantially cheaper – the prices vary between Rs 1,300 and Rs 4,500 per month - than the original ones.

Come March 20, when the patent for Semaglutide expires, the Indian market is expected to see the launch of generic drugs from at least seven pharma companies, at costs ranging from one-third to ...

At least a dozen large Indian drugmakers are set to roll out copies of Novo Nordisk A/S’s blockbuster weight-loss drugs as soon as the patent expires Friday, crashing prices in the country with the ...